Carlsmed financials
$14.09−0.63%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 |
|---|---|
| Revenue | $50.5M |
| Gross profit | $38.0M |
| Gross margin | 75.3% |
| Operating income | -$30.6M |
| Net income | -$30.2M |
| Net margin | −59.8% |
| Diluted EPS | $-2.12 |
| EBITDA | -$30.3M |
| Operating cash flow | -$29.0M |
| Free cash flow | -$30.3M |
| Diluted shares | 14.2M |
Balance sheet
| Period end | Dec 31 |
|---|---|
| Cash & equivalents | $85.8M |
| Short-term investments | $24.0M |
| Total debt | $15.3M |
| Total assets | $130.1M |
| Total liabilities | $31.3M |
| Shareholders' equity | $98.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology